<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02133521</url>
  </required_header>
  <id_info>
    <org_study_id>DLBS1033-0111</org_study_id>
    <nct_id>NCT02133521</nct_id>
  </id_info>
  <brief_title>DLBS1033 for Acute Ischemic Stroke Patients</brief_title>
  <acronym>ADDLIST</acronym>
  <official_title>Addition of DLBS1033 to Standard Therapy for Acute Ischemic Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dexa Medica Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dexa Medica Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind, and controlled clinical study to investigate&#xD;
      the effects of DLBS1033 in conjunction with standard therapy compared to standard therapy&#xD;
      alone in acute ischemic stroke patients. It is hypothesized that the improvement in&#xD;
      functional outcomes as measured by NIHSS and BI as well as the improvement in haemostatic&#xD;
      parameters as measured by thrombocyte aggregation test (TAT), fibrinogen, and d-dimer in DLBS&#xD;
      group will be significantly greater than those in the control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects in this study will be screened consecutively and eligible subjects will be&#xD;
      randomized into two groups and receive the investigational drug, DLBS1033 at a dose of 490 mg&#xD;
      three times daily or its placebo in addition to standard therapy for 28-days course of&#xD;
      therapy. Standard therapy used in this study will consist of: aspirin 80 mg, simvastatin 20&#xD;
      mg, and vitamin B complex.&#xD;
&#xD;
      After hospital admission and diagnosis, patient will be handled as per acute ischemic stroke&#xD;
      management in each study site. Right after the patient is confirmed eligible to the study,&#xD;
      the treatment(s) will be switched immediately into the study treatments. Clinical and&#xD;
      laboratory examinations to evaluate the investigational drug's efficacy will be performed at&#xD;
      baseline and 3, 7,14, and 28 days after study medication initiation; while safety&#xD;
      examinations will be performed at the same time point, but 3 and 14 days after study&#xD;
      medication initiation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>3, 7, 14, and 28 days after study medication</time_frame>
    <description>Change in functional outcomes as measured by NIHSS from its baseline value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Barthel Index (BI)</measure>
    <time_frame>3, 7, 14, and 28 days after study medication</time_frame>
    <description>Change in functional outcomes as measured by BI from its baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombocyte Aggregation Test (TAT)</measure>
    <time_frame>3, 7, 14, and 28 days after study medication</time_frame>
    <description>Change in haemostatic parameter as measured by TAT from its baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen level</measure>
    <time_frame>3, 7, 14, and 28 days after study medication</time_frame>
    <description>Change in haemostatic parameter as measured by fibrinogen level from its baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer level</measure>
    <time_frame>3, 7, 14, and 28 days after study medication</time_frame>
    <description>Change in haemostatic parameter as measured by d-dimer level from its baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>7 and 28 days after study medication</time_frame>
    <description>Liver function measured includes: serum AST, ALT, gamma-GT, total bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>7 and 28 days after study medication</time_frame>
    <description>Renal function measured includes: serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine hematology</measure>
    <time_frame>7 and 28 days after study medication</time_frame>
    <description>Routine hematology measured includes: hemoglobin, hematocrit, RBC, WBC, differentiation of WBC, and platelet count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 - 28 days</time_frame>
    <description>Adverse events, including bleeding events, will be observed and carefully evaluated along the course of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <condition>Partial Anterior Circulation Infarct</condition>
  <condition>Lacunar Anterior Circulation Infarct</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 3 x 1 tablet, given everyday for 28 days of study period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DLBS1033</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DLBS1033 enteric-coated tablet 3 x 490 mg daily, given everyday for 28 days of study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DLBS1033</intervention_name>
    <description>Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet</description>
    <arm_group_label>DLBS1033</arm_group_label>
    <other_name>Disolf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent from the patients or patients' legally acceptable&#xD;
             representatives (must be obtained before any trial related activities).&#xD;
&#xD;
          -  Male or female subjects with age of &gt;18 years at Screening.&#xD;
&#xD;
          -  Patients clinically diagnosed having acute ischemic stroke attack and confirmed by CT&#xD;
             scan.&#xD;
&#xD;
          -  Patients with cerebral infarction subtypes of PACI or LACI as classified by Bamford&#xD;
             criteria.&#xD;
&#xD;
          -  Patients with moderate condition based on National Institutes of Health Stroke Scale&#xD;
             (NIHSS) score of 5-15.&#xD;
&#xD;
          -  Patients present at hospital and receiving first dose of study medication within 72&#xD;
             hours after the onset of the stroke symptoms.&#xD;
&#xD;
          -  Able to take oral medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For females of childbearing potential: pregnancy and lactation period.&#xD;
&#xD;
          -  History of hemorrhagic stroke within the last 3 months.&#xD;
&#xD;
          -  Patients with seizure at the onset of stroke or with regular medication for&#xD;
             seizure/epilepsy.&#xD;
&#xD;
          -  Current or regular use (within the last 1 month) of oral anticoagulants, antiplatelets&#xD;
             other than study medication, and herbal medicines.&#xD;
&#xD;
          -  Patients who have received tissue plasminogen activator (TPA) within 24 hours to&#xD;
             Screening.&#xD;
&#xD;
          -  History of serious head injury within the last 3 months.&#xD;
&#xD;
          -  History of major surgery within the last 3 months.&#xD;
&#xD;
          -  Recent serious cardiovascular conditions, such as myocardial infarction and heart&#xD;
             atrial fibrillation as demonstrated by electrocardiography (ECG).&#xD;
&#xD;
          -  History of congestive heart failure and aortic dissection.&#xD;
&#xD;
          -  Presence of severe renal and hepatic dysfunction, defined as serum creatinine level &gt;&#xD;
             3x upper limit of normal (ULN) or history of hemodialysis, and any of serum ALT, AST,&#xD;
             Gamma-GT level of &gt; 3x ULN, respectively.&#xD;
&#xD;
          -  Presence of acute SIRS.&#xD;
&#xD;
          -  Presence of chronic infections.&#xD;
&#xD;
          -  Patients with higher risks of bleeding.&#xD;
&#xD;
          -  Subjects with uncontrolled hypertension (systolic blood pressure &gt; 185 mmHg or&#xD;
             diastolic blood pressure &gt; 110 mmHg).&#xD;
&#xD;
          -  Subjects with random plasma glucose ≥180 mg/dL and HbA1c ≥ 7.0% at Screening.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to the trial product or related products.&#xD;
&#xD;
          -  Participation in any other clinical studies within 30 days prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulus Sugianto, Sp.S(K), Dr, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Indonesia's Neurologists Organization (Perdossi)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muh. Hamdan, Sp.S(K), MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Department Dr. Soetomo Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dodik Tugasworo, Sp.S(K), MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Department Dr. Kariadi General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dian Cahyani, Sp.S, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Department Budhi Asih Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diah H Soeryaningtias, Sp.S, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Department Haji Surabaya Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gotot S PW, Sp.S, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Department Pasar Rebo Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sugeng Wijayanto, Sp.S, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Department Sidoarjo Regional General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ika Y Margaretha, Sp.S, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Department Fatmawati Regional General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wiwin Sundawiyani, Sp.S, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Islam Jakarta Hospital (RSIJ) Cempaka Putih</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rivan Danuaji, Sp.N(K), MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Department Dr. Moewardi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paulus Sugianto, Sp.S(K), Dr, MD</last_name>
    <email>paulus.sugianto@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurology Department, Dr. Kariadi General Hospital</name>
      <address>
        <city>Semarang</city>
        <state>Central Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dr. Moewardi Hospital</name>
      <address>
        <city>Surakarta</city>
        <state>Central Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rivan Danuaji, Sp.N(K), MD</last_name>
      <phone>+62271 634 634</phone>
    </contact>
    <investigator>
      <last_name>Rivan Danuaji, Sp.N(K), MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ervina A Jayanti Hutabarat, Sp.N, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ira Ristinawati, Sp.N, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Department Islam Jakarta Hospital (RSIJ) Cempaka Putih</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wiwin Sundawiyani, Sp.S, MD</last_name>
      <phone>+6281383144399</phone>
    </contact>
    <investigator>
      <last_name>Wiwin Sundawiyani, Sp.S, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taufik Mesiano, Sp.S, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elfa A Ersyanti, Sp.N, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Department Fatmawati Regional General Hospital</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ika Y Margaretha, Sp.S, MD</last_name>
      <phone>+62852256654666</phone>
    </contact>
    <investigator>
      <last_name>Ika Y Margaretha, Sp.S, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susi Harini, Sp.S, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hastari Sukardi, Sp.S, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arfan Mappalilu, Sp.S, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fritz Sumantri, Sp.S, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maysam Irawati, Sp.S, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuniarti Yuniarti, Sp.S, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fitriany Nasution, Sp.S, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Department, Budhi Asih Hospital</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dian Cahyani, MD., SpS</last_name>
      <phone>+6212 1064 031</phone>
    </contact>
    <investigator>
      <last_name>Dian Cahyani, MD., SpS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ananda Setiabudi, MD., SpS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julintari Indiyani, MD., SpS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Department, Pasar Rebo Hospital</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gotot S PW, Sp. S, MD</last_name>
      <phone>+621 8400 109</phone>
    </contact>
    <investigator>
      <last_name>Gotot S PW, Sp. S, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ridwan Ridwan, Sp. S, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donny H Hamid, Sp. S, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Department Sidoarjo Regional General Hospital</name>
      <address>
        <city>Sidoarjo</city>
        <state>East Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sugeng Wijayanto, Sp.S, MD</last_name>
      <phone>+62812 5940 4413</phone>
    </contact>
    <investigator>
      <last_name>Sugeng Wijayanto, Sp.S, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanifah H W, Sp.S, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andiva S R, Sp.S, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Department, Haji Surabaya Hospital</name>
      <address>
        <city>Surabaya</city>
        <state>East Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Stroke/Cerebrobascular Division, Neurology Department, Dr. Soetomo Hospital</name>
      <address>
        <city>Surabaya</city>
        <state>East Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2014</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBS1033</keyword>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>NIHSS</keyword>
  <keyword>Barthel Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

